Firefly Neuroscience (NASDAQ:AIFF) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Firefly Neuroscience (NASDAQ:AIFF) to a hold rating in a research note published on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Firefly Neuroscience in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Firefly Neuroscience Price Performance

Firefly Neuroscience stock opened at $1.76 on Friday. The stock has a market capitalization of $26.03 million, a PE ratio of -0.98 and a beta of 0.58. Firefly Neuroscience has a 12 month low of $0.62 and a 12 month high of $4.51. The business has a 50 day simple moving average of $1.52 and a 200-day simple moving average of $1.57.

Firefly Neuroscience (NASDAQ:AIFF) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.16) EPS for the quarter. The business had revenue of $0.41 million during the quarter. Firefly Neuroscience had a negative net margin of 1,740.98% and a negative return on equity of 229.99%.

Hedge Funds Weigh In On Firefly Neuroscience

Several large investors have recently modified their holdings of the business. Savvy Advisors Inc. acquired a new position in shares of Firefly Neuroscience in the 3rd quarter valued at $63,000. Geode Capital Management LLC lifted its stake in shares of Firefly Neuroscience by 92.9% in the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after purchasing an additional 58,067 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Firefly Neuroscience in the 4th quarter valued at $53,000. Finally, Vanguard Group Inc. lifted its stake in shares of Firefly Neuroscience by 393.3% in the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock valued at $1,464,000 after purchasing an additional 401,085 shares during the last quarter. Institutional investors and hedge funds own 4.96% of the company’s stock.

Firefly Neuroscience Company Profile

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.